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In the USA, an estimated 51 200 cases of cancer of the bladder are
diagnosed annually and 10 600 deaths from the disease occur each
year (Boring et al, 1994). Bladder cancer currently accounts for 6%
of all new cancer cases in men and 2% of new cancer cases in
women. The most established aetiological risk factors for bladder
cancer are cigarette smoking and occupational exposure to
arylamines (Yu and Ross, 1998). Many other possible aetiological
factors have been extensively explored (e.g. caffeine intake, use of
artificial sweetener), but none have been definitively established as
causative agents. A number of experimental and laboratory studies
have examined the relationship between analgesic use and bladder
cancer risk; the evidence tends to vary by class of formulation.
Phenacetin-based analgesics have been known for a long time to
cause cancer of the renal pelvis in humans (Hultengren et al, 1965;
Angervall et al, 1969) and experimental data indicates that the
compound is carcinogenic to the bladder as well (Johansson, 1981;
Murai et al, 1993). Epidemiological data regarding bladder cancer
risk are relatively sparse, but generally are in support of phenacetin
as a human bladder carcinogen (Fokkens, 1979; McCredie 
et al, 1983; Piper et al, 1985; McCredie and Stewart, 1988).
Acetaminophen use, a phenacetin metabolite, has been examined as
a separate risk factor in a few epidemiological (Piper et al, 1985;
McCredie et al, 1988; Derby et al, 1996) and experimental studies
(Flaks et al, 1985; Hiraga et al, 1985). On balance, the evidence
points towards acetaminophen as being non-carcinogenic to the
bladder. Human data on bladder cancer and non-steroidal anti-
inflammatory drugs (NSAIDs), including aspirin, are largely
lacking. However, a number of rodent studies have shown that
several classes of NSAIDs are powerful inhibitors of chemically-
induced bladder cancer (Grubbs et al, 1993; Klän et al, 1993;
Shibata et al, 1993; Rao et al, 1996), thus raising the possibility that
NSAID intake might protect against bladder cancer development in
humans.
In 1986, we initiated a large-scale case–control study of bladder
cancer in Los Angeles County with one of the primary aims being
the investigation of chronic use of over-the-counter and prescrip-
tion analgesics in relation to bladder cancer risk. We hypothesized
that chronic use of analgesics was associated with increased
bladder cancer risk. This report describes in detail our findings
with respect to individual classes of analgesics by formulation.
MATERIALS AND METHODS
The Los Angeles County Cancer Surveillance Program 
(Bernstein and Ross, 1991), the population-based based
Surveillance, Epidemiology and End Results (SEER) cancer
registry of Los Angeles County, identified 2098 non-Asian
patients aged 25–74 years with histologically confirmed bladder
cancer between 1 January 1987 and 30 April 1996. Among these,
175 patients died before we could contact them or were too ill to
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their physicians and 267 patients refused to be interviewed. Thus,
we interviewed 75% (1582 out of 2098) of all eligible patients.
For each patient interviewed, we sought to recruit a control who
was matched to the index case by sex, date of birth (within 5 years),
race (non-Hispanic White, Hispanic, Black), and neighbourhood of
residence at the time of cancer diagnosis. To search for these
‘neighbourhood’ controls, we followed a standard procedure that
defines a sequence of houses on specified neighbourhood blocks.
We attempted to identify the sex, age and race of all inhabitants of
each housing unit; ‘not at home’ units were systematically revisited
to complete the census. When we failed to find any resident who
met our matching criteria after canvassing 150 housing units, we
excluded race from the matching criteria. If a matched control
based on this relaxed criteria could not be found within a maximum
of 300 housing units, the case was dropped from the study. Sixty-
eight cases were dropped from the study due to lack of a matched
control, and 22 controls were not matched by race to the index case.
In-person, structured interviews were conducted in subjects’
homes. The questionnaire requested information up to 2 years
prior to the diagnosis of cancer for cases and 2 years prior to diag-
nosis of cancer of the index case for matched controls. The ques-
tionnaire included information on demographic characteristics,
height, weight, lifetime use of tobacco and alcohol, usual adult
dietary habits, lifetime occupational history, prior medical condi-
tions and prior use of medications.
In terms of analgesic use, we explicitly listed 44 over-the-
counter and 33 prescription brand-name analgesics in the question-
naire (see Appendix). These brand-named drugs represent all
common analgesics marketed in the USA since the 1950s. A
picture album of the listed drugs was available to the respondent to
assist in their recall of their usage. For each of the listed brand
name analgesics, we first asked the subject whether they had ever
taken the drug 20 or more times over their lifetime. If the answer
was no, the subject was defined as a ‘non-user’. Otherwise, the
subject was further asked if they had ever taken the drug two or
more times a week for 1 month or longer. If the answer was no, the
subject was classified as an ‘irregular user’. Otherwise, the subject
was defined as a ‘regular user’ and was further asked about the
ages at first and last use, duration of use, usual frequency and
dosage of use, and the primary reason for such use. Aside from the
77 brand-name analgesics listed, the subject was asked if they had
taken any other analgesics regularly. If the answer was yes, the
names of the analgesic drugs were recorded, and ages at first and
last use, duration of use, usual frequency and dosage of use, and
the primary reason for use were similarly asked.
The formulations of each of the listed analgesics as well as 
those volunteered by study subjects were established through
numerous pharmaceutical sources, including the annually updated
Physician’s Desk Reference. Each active ingredient of brand-name
analgesics was classified according to formulation as follows:
aspirin, non-aspirin NSAIDs, acetaminophen, phenacetin and
other. Similarly, each active ingredient of non-aspirin NSAIDs was
further classified as propionic acid (such as ibuprofen and
naproxen), acetic acid (such as indomethacin and sulindac),
fenamic acid (such as meclofenamic), salicylic acid (such as
magnesium salicylate and salicylamide), oxicam (such as pirox-
icam), and pyrazolon derivatives (such as phenylbutazone). Age-
specific exposure to a given drug was estimated from the subject’s
reported dose and duration of use at that age. Lifetime cumulative
exposure (g) to a specific class of analgesics was computed by
summing individual age-specific exposures across all ages and all
brand-name drugs containing the active ingredient of interest.
Cumulative exposures among regular users were grouped into
tertiles or above/below median values according to their distribu-
tions among control subjects.
Data were analysed by standard matched-pair methods (Breslow
and Day, 1980). The associations of bladder cancer with various
exposure indices of analgesic use were measured by odds ratios
(ORs) and their corresponding 95% confidence intervals (CIs) and
P-values. Conditional logistic regression models were used to
examine the relationship between analgesic use and bladder cancer
risk with adjustment for other risk factors for bladder cancer (ciga-
rette smoking and duration of employment as hairdresser/barber).
Pairs in which either the case or the control failed to answer the
relevant questions were eliminated from the corresponding
analysis. ORs with 2-sided P-values less than 0.05 were consid-
ered statistically significant. All P-values quoted are 2-sided.
RESULTS
The mean age of the patients at diagnosis of bladder cancer was 58
years. Most patients were non-Hispanic Whites (n = 1413), with
the remaining being Hispanic Whites (n = 58), African-Americans
(n = 42) and Native Americans (n = 1). On average, bladder cancer
patients had a lower level of education than controls. The OR for
bladder cancer was 0.56 (95% CI 0.48–0.67) for those who had
attended college (13 years or more of schooling) compared with
those who had a high school education or lower. Thus, all ORs
presented below were adjusted for level of education (high school
or less, college or above).
Relative to lifetime non-users of analgesics, irregular users of
analgesics exhibited no increase in risk of bladder cancer (OR =
0.95, 95% CI 0.67–1.34), whereas regular users of analgesics
(used at least twice a week for 1 month or longer) showed a 20%
decrease in risk (OR = 0.81, 95% CI 0.68–0.96) relative to non- or
irregular users after adjustment for cigarette smoking and duration
of employment as hairdresser/barber (Table 1).
Table 2 presents the individual relationships between bladder
cancer and the phenacetin-based and acetaminophen-based 
analgesics. After adjustment for cigarette smoking, duration of
employment as hairdresser/barber and use of other analgesics,
phenacetin use was related to a statistically non-significant 50%
increase in bladder cancer risk that was, however, dose-dependent
(P = 0.03). The highest tertile of lifetime exposure was associated
with a 1.8-fold increase in risk relative to non/irregular use of any
analgesic. Acetaminophen use, on the other hand, was not related
to increased risk (OR = 0.85, 95% CI 0.60–1.19), and there was no
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Table 1 Use of analgesics and risk of bladder cancer
Use of any analgesic Cases Controls ORa (95% CI)
Non/Irregular user 961 920 1.0
Regular userb 553 594 0.81 (0.68–0.96)
aAdjusted for level of education, current cigarette smoking status, number of
cigarettes smoked per day, number of years of cigarette smoking, and
number of years employed as hairdresser/barber. bUsed at least twice a
week for 1 month or longer.dose–response relationship with lifetime exposure (P = 0.80).
Since use of different categories of analgesics are likely to be
correlated, mutual adjustment for such highly correlated variables
may not adequately control for the effect of confounding. One way
of addressing this issue is to evaluate exclusive use of each type of
analgesic. Table 2 shows that results based on exclusive use were
consistent with those based on any use of acetaminophen. There
were no exclusive users of phenacetin because all phenacetin-
containing analgesics consumed by study subjects also contained
aspirin.
Table 3 shows risk of bladder cancer by formulation subclass 
of NSAIDs. Except for pyrazolon derivatives, all other formula-
tion subclasses of NSAIDs exhibited an inverse, dose-dependent
association between intake and risk. However, the strength of the
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Table 2 Cumulative lifetime consumption of phenacetin- and acetaminophen-based analgesics in relation to risk of bladder cancer
Any users Exclusive users
Category of analgesic Ca/Co ORa (95% CI) Ca/Co ORb (95% CI)
Phenacetin
Regular use 82/64 1.52 (0.85–2.73) – –
Cumulative lifetime exposure (g)
< 46 25/18 1.35 (0.60–3.07) – –
46–250 27/20 1.64 (0.73–3.70) – –
251+ 21/20 1.85 (0.77–4.43) – –
Acetaminophen
Regular use 224/244 0.85 (0.60–1.19) 60/50 1.03 (0.67–1.58)
Cumulative lifetime exposure (g)
< 114 62/75 0.75 (0.47–1.20) 27/21 1.07 (0.56–2.04)
114–885 57/82 0.68 (0.43–1.09) 17/17 0.82 (0.39–1.72)
886+ 90/74 1.43 (0.87–2.35) 15/7 1.93 (0.73–5.11)
aReference group = non/irregular users of analgesics. ORs after adjustment for education (less than college, college or above),
current cigarette smoking status, number of cigarettes smoked per day, number of years of cigarette smoking, number of years
employed as hairdresser/barber, NSAID use, and use of the other class of analgesics listed in the table. bORs after adjustment for
education (less than college, college or above), current cigarette smoking status, number of cigarettes smoked per day, number of
years of cigarette smoking, and number of years employed as hairdresser/barber.
Table 3 Cumulative lifetime consumption of various classes of NSAIDs in relation to risk of bladder cancer
Any users Exclusive users
Category of analgesic Ca/Co ORa (95% CI) Ca/Co ORb (95% CI)
Aspirin
Regular use 399/420 0.88 (0.70–1.12) 175/187 0.85 (0.66–1.09)
Cumulative lifetime exposure (g)
< 245 156/139 0.99 (0.73–1.34) 86/68 1.04 (0.72–1.49)
245–1242 126/136 0.94 (0.68–1.30) 61/67 0.92 (0.61–1.36)
1243+ 107/135 0.63 (0.43–0.92) 25/48 0.49 (0.29–0.84)
Other salicylic acids
Regular use 48/53 0.81 (0.45–1.45) – –
Cumulative lifetime exposure (g)
< 168 24/25 0.92 (0.43–1.97) – –
168+ 20/24 0.65 (0.31–1.37) – –
Acetic acids
Regular use 30/54 0.54 (0.31–0.94) 9/15 0.53 (0.21–1.36)
Cumulative lifetime exposure (g)
< 27 18/22 0.68 (0.31–1.47) 6/3 1.05 (0.22–4.97)
27+ 10/25 0.46 (0.21–1.03) 3/10 0.37 (0.09–1.49)
Propionic acids
Regular use 131/151 0.70 (0.49–0.99) 37/48 0.61 (0.37–0.99)
Cumulative lifetime exposure (g)
< 144 61/65 0.81 (0.51–1.28) 21/24 0.75 (0.39–1.43)
144+ 63/79 0.55 (0.34–0.87) 14/22 0.46 (0.22–0.98)
Oxicam
Regular use 18/17 0.92 (0.42–2.02) – –
Pyrazolon derivatives
Regular use 13/6 2.03 (0.68–6.07) – –
aReference group = non/irregular users of analgesics. ORs after adjustment for education (less than college, college or above),
current cigarette smoking status, number of cigarettes smoked per day, number of years of cigarette smoking, number of years
employed as hairdresser/barber, use of phenacetin, acetaminophen, and the other classes of analgesics listed in the table. bORs
after adjustment for education (less than college, college or above), current cigarette smoking status, number of cigarettes smoked
per day, number of years of cigarette smoking, and number of years employed as hairdresser/barber.association seemed to vary by formulation. The strongest protec-
tive effect was observed with acetic acids (overall OR = 0.54)
while aspirin/other salicylic acids (overall ORs of 0.88 and 0.81
respectively) and oxicam (overall OR = 0.92) showed the weakest
protective effects. Propionic acids exhibited intermediate effects
(overall OR about 0.70). When the analysis was confined to exclu-
sive users of individual formulation subclasses of NSAIDs, results
similar to those based on all subjects were obtained.
In contrast to the inverse exposure-risk relationship of other
NSAIDs with bladder cancer, intake of pyrazolon derivatives was
associated with a 2.0-fold increase in risk (Table 3). However, rela-
tively few subjects had used these drugs (only 13 cases and six
controls and all took phenylbutazone), and the relative risk esti-
mate was not statistically significant.
DISCUSSION
To our knowledge, the present study is the largest case–control
study of bladder cancer ever conducted in a single, geographically
defined study population. Our study was specifically designed to
examine the association between analgesic use and bladder cancer,
and detailed data were collected on this exposure. Our data demon-
strate that sustained use of analgesics is not related to an increased
risk of bladder cancer, as it is for cancer of the renal pelvis
(McCredie et al, 1982) and parenchyma (Gago-Dominguez et al,
1999). In fact, compared with non- or irregular users, regular anal-
gesic users were at an overall decreased risk of bladder cancer (OR
= 0.81, 95% CI 0.68–0.96). However, there were clear differences
in both the direction and strength of the associations between
different classes of analgesics and bladder cancer risk. Intake of
phenacetin was positively related to bladder cancer risk in a dose-
dependent manner while intake of its major metabolite in humans,
acetaminophen, was unrelated to risk. Intake of all classes of
NSAIDs, except pyrazolon derivatives, were negatively associated
with bladder cancer risk, with suggestive evidence that the protec-
tive effect varies in strength by subcategories of formulation.
Acetic acids seemed to exhibit the strongest protective effect
whereas aspirin/other salicylic acids and oxicam showed the
weakest protection.
It is unlikely that recall bias could explain our results on NSAID
use and bladder cancer. We have indirect evidence to support the
absence of such a bias. A parallel case–control study of renal cell
carcinoma that we conducted used the same set of medication
questions as the current study as well as the same team of inter-
viewers. Unlike the present results of a protective effect for cancer
in NSAID users, the former study demonstrated statistically signif-
icant increased cancer risk among all categories of analgesic users
(Gago-Dominguez et al, 1999). More importantly, the renal cell
carcinoma study included a drug validation component in which
all self-reported use of prescription analgesics was validated
against physician/clinic records. Rates of concordance were
remarkably similar between case and control groups, indicating a
general lack of recall bias among cancer patients.
Chronic use of analgesics was first linked to the development of
malignant growth in the urothelium through a series of case reports
which documented cancer of the renal pelvis occurring in heavy
users of phenacetin (Hultengren et al, 1965; Angervall et al, 1969).
Johansson and Wahlqvist (1977) reviewed a series of case reports
which documented bladder cancer among individuals with a
history of phenacetin abuse. These uncontrolled observations were
later followed by a few case–control studies (Fokkens, 1979;
McCredie et al, 1983; Piper et al, 1985; McCredie and Stewart,
1988). Although fairly strong associations between regular use and
increased risk were found in these studies, a dose–response rela-
tionship was demonstrated only in the Australian study (McCredie
et al, 1983). Experimental studies have found phenacetin to cause
bladder cancer in rats (Johansson, 1981; Murai et al, 1993). The
present study confirms that sustained use of phenacetin is a
bladder cancer risk factor, conferring a 1.5-fold excess risk among
regular users of this drug. Phenacetin has been absent from all
drugs manufactured in the USA since 1987.
Acetaminophen has been examined as a separate risk factor for
bladder cancer in both an Australian and a US study (Piper et al,
1985; McCredie and Stewart, 1988). The results suggested that
heavy use of acetaminophen-containing analgesics does not
increase bladder cancer risk. A more recent case–control study
(Derby et al, 1996) found a small, non-significant increased risk of
bladder cancer among subjects with heavy acetaminophen expo-
sure (OR = 1.3). Flaks et al (1985) found that long-term oral
administration of acetaminophen induces transitional cell papil-
lomas of the bladder, suggesting that acetaminophen could be a
weak bladder carcinogen in this species, but Hiraga et al (1985)
found no such evidence in a different rat species. Our data suggest
that regular use of acetaminophen is not associated with the devel-
opment of bladder cancer in humans.
The potential chemopreventive effects of aspirin on chemically-
induced bladder cancer has been studied in rodents; results are
mixed. Rao et al (1996) and Cohen et al (1989) noted no difference
in incidence of bladder carcinomas between rats fed carcinogen
only and those fed aspirin (up to 800 ppm in Rao et al and 
5000 ppm in Cohen et al), concurrently with the carcinogen. On
the other hand, Murasaki et al (1984) reported a statistically signif-
icant reduction in bladder cancer incidence in rats fed aspirin
(5000 ppm) concurrently with the carcinogen relative to rats fed
the carcinogen only (ten of 27 rats in former group had cancer vs
18 of 21 in latter group). Klän et al (1993) also observed a signifi-
cant reduction in bladder cancer incidence among rats fed aspirin
(1000 ppm) and carcinogen compared to rats fed carcinogen only
(1/29 vs 8/29). Thus, there is suggestive experimental evidence
that high-dose aspirin can protect against bladder cancer develop-
ment.
There also exists experimental evidence in support of other
types of NSAIDs as chemopreventive agents of bladder carcino-
genesis. Acetic acids (indomethacin, sulindac) at dosage levels of
7.5 ppm or higher have been shown to reduce the incidence of
carcinogen-induced bladder cancer by 70% or more (Grubbs et al,
1993; Shibata et al, 1993; Rao et al, 1996). Similarly, propionic
acids (ketoprofen) and oxicams (piroxicam) reduce cancer inci-
dence by comparable amounts (Moon et al, 1993; Rao et al, 1996).
Our study supports these experimental findings.
In the current study, intake of pyrazolon derivatives unlike the
other NSAIDs was associated with a substantial, although statisti-
cally non-significant, twofold increased risk of bladder cancer.
Importantly there is experimental support for this epidemiological
observation as well. Phenylbutazone, a pyrazolon derivative,
induces transitional cell papillomas of the bladder in rats (Kari et
al, 1995).
The present study provides the first detailed set of epidemiolog-
ical data strongly suggesting that NSAIDs are protective against
bladder cancer development. The large sample size allowed us 
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to examine risk by categories of formulation. Excluding the
pyrazolon derivatives acetic acids were the most effective and sali-
cylic acids (including aspirin) as least effective in reducing bladder
cancer risk. The only prior human data on this issue were from a
large prospective study which examined aspirin use and risk of
fatal cancer, in which no association was observed with mortality
from cancers of the urinary tract overall (Thun et al, 1993).
Epidemiological studies have revealed that NSAIDs are
promising candidates for chemoprevention against cancer of the
colon. Experimental data are supportive of this hypothesis and also
suggest that NSAIDs might provide protection against cancers of
the mammary gland, skin and liver as well as the urinary bladder
(Moon et al, 1992; Kelloff et al, 1994; Giardiello et al, 1995;
Denda et al, 1997). The preventive mechanisms remain to be eluci-
dated in detail but have been postulated to involve their inhibition
of cyclooxygenase (COX), thereby inhibiting production of
prostaglandins which influence tumour growth through both by
stimulating cell proliferation and by disturbing immunological
surveillance (Marnett, 1992; Giardiello et al, 1995; Lupulescu,
1996). There are two COX isoenzymes in humans, COX-1 and
COX-2, and limited evidence suggests that COX-2 is the pivotal
COX enzyme involved in carcinogenesis. COX-2, in contrast to
the constitutively expressed COX-1 which contributes to physio-
logical functions in most tissues, is inducible and has proven
involvement in inflammatory responses and cell proliferation
(Herschman, 1994). It is known that COX-2 is highly expressed in
colon, stomach, skin and mammary tumours (Kargman et al, 1995;
Müller-Decker et al, 1995; DuBois et al, 1996; Liu et al, 1996;
Ristimäki et al, 1997), in conjunction with increased levels of
prostaglandins (Lupulescu, 1996).
There is experimental evidence implicating the involvement of
COX-2 in bladder cancer carcinogenesis. Okajima et al (1998)
reported statistically significant, dose-dependent reductions
(30–65%) in tumour incidence in nitrosamine-treated rats when
the animals were administered a selective COX-2 inhibitor concur-
rently with carcinogen treatment.
This is the first epidemiological study to demonstrate a possible
chemopreventive effect of long-term NSAID intake on bladder
cancer development. Our observation has obvious public health
significance, given that bladder cancer is the 11th commonest
cancer worldwide, and the sixth commonest cancer in the USA
(Kosary et al, 1995; Yu et al, 1998). Earlier, we had reported that
sustained use of NSAID might contribute to the development of
renal cell carcinoma, and that such exposure might explain
approximately 20% of the cases diagnosed in Los Angeles County
(Gago-Dominguez et al, 1999). On the other hand, there is
growing evidence that NSAID use protects against colorectal
cancer, Alzheimer’s disease and ischaemic heart disease (Steering
Committee of the Physicians’ Health Study Research Group,
1989; Giovannucci et al, 1995; McGeer et al, 1996). This study
suggests that NSAID use also may protect against another rela-
tively common cancer in the USA as well as worldwide. If proven
to be true, it will represent an important new dimension to the
risk–benefit equation of NSAID use. One needs to bear in mind
that while the incidence of renal cell carcinoma in US non-
Hispanic Whites is about 6/100 000 (Yu et al, 1999), the compa-
rable figures for bladder cancer, colorectal cancer, Alzheimer’s
disease and fatal ischaemic heart disease are 20, 44, 95 and 204 per
100 000, respectively (Kokmen et al, 1993; Liu et al, 1996;
National Center for Health Statistics, 1996).
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APPENDIX
Brand-name analgesics (over-the counter and
prescription) categorized by formulation
Aspirin only: Momentum, regular aspirin, extra strength aspirin,
buffered aspirin, arthritis strength Bufferin, regular Anacin,
arthritis pain formula Anacin, Cama, 4-way cold tablet, Midol,
Alka-seltzer, aspirin with codeine, Percodan, Equagesic, Talwin
compound.
Aspirin + Phenacetin: APC, ASA compound, Empirin compound,
Empirin with codeine, APC with codeine, Darvon compound,
Fiorinal, Norgesic or Norgesic Forte, Phenaphen, Buff-a-comp,
Synalgos.
Aspirin + Acetaminophen: extra strength Excedrin, Vanquish,
Goody’s headache powders.
Aspirin + Other NSAID + Acetaminophen: Excedrin.
Aspirin + Other NSAID: Stanback, BC powder or tablets.
Acetaminophen only: regular strength Tylenol, extra strength
Tylenol, Cotylenol, generic acetaminophen, Anacin-3 regular
strength or aspirin-free Anacin, Anacin-3 maximum strength or
aspirin-free Anacin, Excedrin PM or aspirin-free Excedrin, regular
strength Datril, extra strength Datril, Comtrex, Coricidin, Dristan
or advanced formula Dristan, Nyquil, Robitussin night relief, Sine-
aid, Sinutab, Triamicin, Bromoseltzer, Pamprin, Tempra, Tylenol
with codeine, Tylox, Darvocet, Percocet-5, Midrin, Valadol,
Percogesic.
Acetaminophen + Phenacetin: Repan.
Acetaminophen + Other NSAID: Bancaps, Arthralgen.
Phenacetin only: Wigraine.
Phenacetin + Other NSAID: Medache.
Other NSAID only: other salicylic acids: Doan’s pill; propionic
acids: Advil, Nuprin, Motrin, Anaprox, Naprosyn, Nalfon; acetic
acids: Clinoril, Indocin; pyrazolon derivatives: Phenylbutazone;
Oxicam: Feldene.
Narcotic analgesics: Darvon, Talwin or Talwin 50.
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